RxDoctor Payments Data

Roohi Riazi, NP

Primary Care · Stafford, VANPI 1336461201

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 25.0% of the total.

$1,748in general payments, 2019–2025

Across 93 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$437
  • AbbVie$407
  • Novo Nordisk$129
  • Amgen$117
  • Lilly USA, LLC$91
  • Abbott$76
  • plus $490 from 17 others

What the payments were for

  • Food & beverage$1,748100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,748 in reported general payments places this provider in the 75th percentile of 142 primary care providers in Virginia.

See all primary care providers in Virginia

Medicare billing

Part B allowed, 2024
$70,153
Medicare patients
394
Services billed
2,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$12,972
Albuterol Sulfate HfaAlbuterol Sulfate112$1,974
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,606
Ofloxacin37$1,030
Atorvastatin Calcium84$736
Losartan Potassium41$586
Ventolin HfaAlbuterol Sulfate11$569
FenofibrateFenofibrate Nanocrystallized17$552
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst34$522
Omeprazole38$520
Amoxicillin147$512
Pantoprazole Sodium34$449
Amlodipine Besylate81$441
Diclofenac Sodium43$435
Levothyroxine Sodium68$434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$129$12,97211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 142 primary care providers in Virginia.

Other primary care in Stafford

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →